These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 6531729)

  • 21. Transient levodopa withdrawal in Parkinson's disease.
    Maesner JE
    Clin Pharm; 1987 Jan; 6(1):22. PubMed ID: 3816104
    [No Abstract]   [Full Text] [Related]  

  • 22. Conjugate eye deviations as dyskinesias induced by levodopa in Parkinson's disease.
    LeWitt PA
    Mov Disord; 1998 Jul; 13(4):731-4. PubMed ID: 9686783
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of Parkinson's disease.
    Lieberman A
    Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):339-43. PubMed ID: 8507903
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparative study of bromocriptine and levodopa in Parkinson's disease.
    Duvoisin RC; Mendoza MM; Yahr MD
    Adv Biochem Psychopharmacol; 1980; 23():271-5. PubMed ID: 7395618
    [No Abstract]   [Full Text] [Related]  

  • 25. Involvement of serotonin in clinical features of Parkinson's disease and complications of L-DOPA therapy.
    Melamed E; Zoldan J; Friedberg G; Ziv I; Weizmann A
    Adv Neurol; 1996; 69():545-50. PubMed ID: 8615179
    [No Abstract]   [Full Text] [Related]  

  • 26. [Benefit of L-DOPA-without-DCI (decarboxylase inhibitor) therapy on wearing-off phenomenon in advanced stages of Parkinson's disease patients].
    Hironishi M; Miwa H; Kondo T
    No To Shinkei; 2002 Feb; 54(2):127-32. PubMed ID: 11889758
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Levodopa compared with bromocriptine in the treatment of Parkinson's disease.
    Godwin-Austen RB
    Adv Biochem Psychopharmacol; 1980; 23():261-5. PubMed ID: 7395616
    [No Abstract]   [Full Text] [Related]  

  • 28. Melanoma, Parkinson's disease and levodopa: causal or spurious link? A review of the literature.
    Zanetti R; Loria D; Rosso S
    Melanoma Res; 2006 Jun; 16(3):201-6. PubMed ID: 16718266
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The evolution and origin of motor complications in Parkinson's disease.
    Obeso JA; Rodriguez-Oroz MC; Chana P; Lera G; Rodriguez M; Olanow CW
    Neurology; 2000; 55(11 Suppl 4):S13-20; discussion S21-3. PubMed ID: 11147505
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Motor complications of Parkinson's disease.
    Martignoni E; Riboldazzi G; Calandrella D; Riva N
    Neurol Sci; 2003 May; 24 Suppl 1():S27-9. PubMed ID: 12774208
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa.
    Hauser RA; Rascol O; Korczyn AD; Jon Stoessl A; Watts RL; Poewe W; De Deyn PP; Lang AE
    Mov Disord; 2007 Dec; 22(16):2409-17. PubMed ID: 17894339
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Levodopa in the treatment of Parkinson's disease: current controversies.
    Gerlach M; Reichmann H; Riederer P
    Mov Disord; 2005 May; 20(5):643; author reply 643-4. PubMed ID: 15732130
    [No Abstract]   [Full Text] [Related]  

  • 33. Treatment of Parkinson's disease: levodopa as the first choice.
    Katzenschlager R; Lees AJ
    J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Behavioral indicators of hallucinosis in levodopa-treated Parkinson's disease.
    Glantz RH; Bieliauskas L; Paleologos N
    Adv Neurol; 1987; 45():417-20. PubMed ID: 3825719
    [No Abstract]   [Full Text] [Related]  

  • 35. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.
    Holloway RG; Shoulson I; Fahn S; Kieburtz K; Lang A; Marek K; McDermott M; Seibyl J; Weiner W; Musch B; Kamp C; Welsh M; Shinaman A; Pahwa R; Barclay L; Hubble J; LeWitt P; Miyasaki J; Suchowersky O; Stacy M; Russell DS; Ford B; Hammerstad J; Riley D; Standaert D; Wooten F; Factor S; Jankovic J; Atassi F; Kurlan R; Panisset M; Rajput A; Rodnitzky R; Shults C; Petsinger G; Waters C; Pfeiffer R; Biglan K; Borchert L; Montgomery A; Sutherland L; Weeks C; DeAngelis M; Sime E; Wood S; Pantella C; Harrigan M; Fussell B; Dillon S; Alexander-Brown B; Rainey P; Tennis M; Rost-Ruffner E; Brown D; Evans S; Berry D; Hall J; Shirley T; Dobson J; Fontaine D; Pfeiffer B; Brocht A; Bennett S; Daigneault S; Hodgeman K; O'Connell C; Ross T; Richard K; Watts A;
    Arch Neurol; 2004 Jul; 61(7):1044-53. PubMed ID: 15262734
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Moderate Parkinson's disease. Strategies for maximizing treatment.
    Silverstein PM
    Postgrad Med; 1996 Jan; 99(1):52-4, 61-3, 67-8, passim. PubMed ID: 8539210
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimizing clinical outcomes in residents with Parkinson's disease. Introduction.
    Libow LS
    J Am Med Dir Assoc; 2006 Sep; 7(7 Suppl 2):3. PubMed ID: 17948615
    [No Abstract]   [Full Text] [Related]  

  • 38. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial.
    Shoulson I; Oakes D; Fahn S; Lang A; Langston JW; LeWitt P; Olanow CW; Penney JB; Tanner C; Kieburtz K; Rudolph A;
    Ann Neurol; 2002 May; 51(5):604-12. PubMed ID: 12112107
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patterns of initial pharmacotherapy for Parkinson's disease in the United States.
    Huse DM; Castelli-Haley J; Orsini LS; Lenhart G; Abdalla JA
    J Geriatr Psychiatry Neurol; 2006 Jun; 19(2):91-7. PubMed ID: 16690994
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Initial management and adaptation of Parkinson's disease treatment].
    Gérard JM
    Rev Med Brux; 2008 Sep; 29(4):229-31. PubMed ID: 18949969
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.